0000899243-18-006002.txt : 20180301
0000899243-18-006002.hdr.sgml : 20180301
20180301204917
ACCESSION NUMBER: 0000899243-18-006002
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180227
FILED AS OF DATE: 20180301
DATE AS OF CHANGE: 20180301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: El-Hibri Fuad
CENTRAL INDEX KEY: 0001380185
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 18659772
MAIL ADDRESS:
STREET 1: 2273 RESEARCH BLVD, SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-27
0
0001367644
Emergent BioSolutions Inc.
EBS
0001380185
El-Hibri Fuad
400 PROFESSIONAL DRIVE, SUITE 400
GAITHERSBURG
MD
20879
1
1
1
0
Chairman
Common Stock
2018-02-27
4
M
0
9794
A
1540010
D
Common Stock
2018-02-27
4
F
0
2385
49.64
D
1537625
D
Common Stock
2018-02-28
4
M
0
9723
A
1547348
D
Common Stock
2018-02-28
4
F
0
2368
49.97
D
1544980
D
Common Stock
4344250
I
By Intervac, L.L.C.
Common Stock
1524155
I
By Biovac, L.L.C.
Restrictive Stock Units
2018-02-27
4
A
0
19288
0.00
A
Common Stock
19288
81352
D
Employee Stock Options (Right to Buy)
49.64
2018-02-27
4
A
0
38577
0.00
A
2025-02-26
Common Stock
38577
38577
D
Restrictive Stock Units
2018-02-27
4
M
0
9794
0.00
D
Common Stock
9794
71558
D
Restrictive Stock Units
2018-02-28
4
M
0
9723
0.00
D
Common Stock
9723
61835
D
Restricted stock units convert into common stock on a one-for-one basis.
Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.
On February 27, 2018, Mr. El-Hibri was granted 38,577 stock options vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.
On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.
On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.
/s/ Carl A. Valenstein, attorney-in-fact
2018-03-01